In this issue:
Three-year PROs with bimekizumab for plaque psoriasis
Benefits and costs of biologics and phototherapy
Serious infection risk with systemic treatments for psoriasis
Biologic therapies as first-line systemic treatment for psoriasis
Circulating metabolites associated with psoriasis
Infection risk in psoriasis patients new to biologics
Picankibart for moderate-to-severe plaque psoriasis
Impact of early psoriasis treatment on disease recurrence
Apremilast in paediatric plaque psoriasis
Sodium-glucose cotransporter-2 inhibitors for psoriasis and type 2 diabetes
Please login below to download this issue (PDF)